Loading
This international trial of infant leukaemia found no benefit from adding myeloid-style chemotherapy courses, and confirmed that KMT2A-rearranged infants remain a high-risk group with survival under 50 percent, setting the baseline that blinatumomab has since improved.
International trial of 651 infants with ALL treated on the Interfant backbone, with 240 medium- and high-risk KMT2A-rearranged infants randomised to standard lymphoid-style consolidation or myeloid-style (ADE and MAE) courses; allogeneic transplant was indicated for high-risk patients.
Six-year event-free survival was 46.1 percent overall; there was no difference between consolidation arms (39.3 versus 37.2 percent), and KMT2A-rearranged infants had 36 percent event-free survival against 74 percent for germline KMT2A.
Interfant-06 is the backbone and control benchmark for infant ALL; the successor Interfant-21 adds blinatumomab after this trial showed chemotherapy intensification had reached its limit.
Shares Rob Pieters, Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year).
Shares Interfant-06, Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year).
Shares Interfant-06, Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year).